Skip to main content
Figure 3 | Cancer Cell International

Figure 3

From: The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma

Figure 3

Column graphs of cell cycle analysis. Following exposure for 72 hours to trastuzumab, heregulin-β1 or the heregulin-β1-trastuzumab combination histograms were analyzed with deconvolution software and expressed as column graphs. A) Significant alterations within the G1 phase were observed in MCF-7 cells exposed to trastuzumab and the heregulin-β1-trastuzumab combination; B) Significant alterations in the S-phase were observed in SK-Br-3 cells exposed to heregulin-β1 compared to the untreated control. [EGF did not perpetuate noteworthy accumulation or alterations in cell cycle kinetics].

Back to article page
\